Now showing items 1-1 of 1

    • Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response 

      Jernström, Sandra Johanna; Hongisto, Vesa; Leivonen, Suvi-Katri; Due, Eldri Undlien; Tadele, Dagim Shiferaw; Edgren, Henrik; Kallioniemi, Olli; Perälä, Merja; Mælandsmo, Gunhild; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-03-21)
      Background<br> Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib, many patients do not benefit from these drugs. Therefore, in-depth understanding of the mechanisms ...